Mitochondrial ATP Synthase is a Target of Oxidative Stress in Neurodegenerative Diseases
- PMID: 35237666
- PMCID: PMC8882969
- DOI: 10.3389/fmolb.2022.854321
Mitochondrial ATP Synthase is a Target of Oxidative Stress in Neurodegenerative Diseases
Abstract
The mitochondrial ATP synthase is responsible for the production of cellular ATP, and it does so by harnessing the membrane potential of the mitochondria that is produced by the sequential oxidation of select cellular metabolites. Since the structural features of ATP synthase were first resolved nearly three decades ago, significant progress has been made in understanding its role in health and disease. Mitochondrial dysfunction is common to neurodegeneration, with elevated oxidative stress a hallmark of this dysfunction. The patterns of this oxidative stress, including molecular targets and the form of oxidative modification, can vary widely. In this mini review we discuss the oxidative modifications of ATP synthase that have been observed in Alzheimer's disease, Parkinson's disease, and Huntington's disease. Oxidative modifications of ATP synthase in Alzheimer's disease are well-documented, and there is a growing body of knowledge on the subject in Parkinson's disease. The consideration of ATP synthase as a pharmacological target in a variety of diseases underlines the importance of understanding these modifications, both as a potential target, and also as inhibitors of any pharmacological intervention.
Keywords: ATP synthase; mitochondria; neurodegenarative disease; oxidative phoshorylation; oxidative stress.
Copyright © 2022 Ebanks and Chakrabarti.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Power Failure of Mitochondria and Oxidative Stress in Neurodegeneration and Its Computational Models.Antioxidants (Basel). 2021 Feb 3;10(2):229. doi: 10.3390/antiox10020229. Antioxidants (Basel). 2021. PMID: 33546471 Free PMC article. Review.
-
Mitochondrial importance in Alzheimer's, Huntington's and Parkinson's diseases.Adv Exp Med Biol. 2012;724:205-21. doi: 10.1007/978-1-4614-0653-2_16. Adv Exp Med Biol. 2012. PMID: 22411245 Review.
-
Oxidative Stress: A Key Modulator in Neurodegenerative Diseases.Molecules. 2019 Apr 22;24(8):1583. doi: 10.3390/molecules24081583. Molecules. 2019. PMID: 31013638 Free PMC article. Review.
-
Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.J Neurol Sci. 2005 Jun 15;233(1-2):145-62. doi: 10.1016/j.jns.2005.03.012. J Neurol Sci. 2005. PMID: 15896810 Review.
-
From the Structural and (Dys)Function of ATP Synthase to Deficiency in Age-Related Diseases.Life (Basel). 2022 Mar 10;12(3):401. doi: 10.3390/life12030401. Life (Basel). 2022. PMID: 35330152 Free PMC article. Review.
Cited by
-
Reprogramming of adult human dermal fibroblasts to induced dorsal forebrain precursor cells maintains aging signatures.Front Cell Neurosci. 2023 Jan 30;17:1003188. doi: 10.3389/fncel.2023.1003188. eCollection 2023. Front Cell Neurosci. 2023. PMID: 36794263 Free PMC article.
-
Analysis of mitochondrial dynamics and function in the retinal pigment epithelium by high-speed high-resolution live imaging.Front Cell Dev Biol. 2022 Oct 28;10:1044672. doi: 10.3389/fcell.2022.1044672. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36393836 Free PMC article.
-
Pyrroloquinoline quinone drives ATP synthesis in vitro and in vivo and provides retinal ganglion cell neuroprotection.Acta Neuropathol Commun. 2023 Sep 8;11(1):146. doi: 10.1186/s40478-023-01642-6. Acta Neuropathol Commun. 2023. PMID: 37684640 Free PMC article.
-
The mitochondrial Hsp70 controls the assembly of the F1FO-ATP synthase.Nat Commun. 2023 Jan 3;14(1):39. doi: 10.1038/s41467-022-35720-5. Nat Commun. 2023. PMID: 36596815 Free PMC article.
-
Activation of the Keap1/Nrf2/HO-1 Pathway by "Tianyu" Pairing: Implications for Inflammation and Oxidative Stress in Rheumatoid Arthritis.Endocr Metab Immune Disord Drug Targets. 2025;25(6):479-491. doi: 10.2174/0118715303307608240812114651. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39192656
References
Publication types
LinkOut - more resources
Full Text Sources